Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide

Michael Halpern, S. Sorensen, D. Covert, J. Hutton

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We analysed retrospective US medical claims data to evaluate longitudinal usage patterns (modification of treatment over time) for glaucoma patients receiving the ophthalmic carbonic anhydrase inhibitors (CAIs) brinzolamide or dorzolamide. Patients enrolled in a healthcare plan at least 2 months before and 6 months after their first CAI pharmacy claim were eligible. Treatment failures, patients who switched off CAI and/or added concomitant glaucoma medications, were calculated at 1, 2, and 6 months. Six hundred and twenty-six patients met the inclusion criteria, 220 for brinzolamide and 406 for dorzolamide. Overall 6 months treatment failure rates were 49.1% and 53.2% for brinzolamide and dorzolamide, respectively. Six month failure rate due to discontinuing CAI only were 20.9% for brinzolamide and 24.6% for dorzolamide, while median days to treatment failure were 160 and 106, respectively (p=0.027). Evaluation of differences in longitudinal usage patterns for CAIs may be helpful in determining appropriate treatments for glaucoma patients.

Original languageEnglish (US)
Pages (from-to)111-120
Number of pages10
JournalJournal of Medical Economics
Volume3
Issue number111-120
StatePublished - 2000
Externally publishedYes

Fingerprint

dorzolamide
Carbonic Anhydrase Inhibitors
Glaucoma
Treatment Failure
Therapeutics
brinzolamide
Delivery of Health Care

Keywords

  • Carbonic anhydrase inhibitors
  • Glaucoma
  • Resource utilisation
  • Retrospective analysis
  • Treatment failure

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide. / Halpern, Michael; Sorensen, S.; Covert, D.; Hutton, J.

In: Journal of Medical Economics, Vol. 3, No. 111-120, 2000, p. 111-120.

Research output: Contribution to journalArticle

Halpern, M, Sorensen, S, Covert, D & Hutton, J 2000, 'Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide', Journal of Medical Economics, vol. 3, no. 111-120, pp. 111-120.
Halpern, Michael ; Sorensen, S. ; Covert, D. ; Hutton, J. / Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide. In: Journal of Medical Economics. 2000 ; Vol. 3, No. 111-120. pp. 111-120.
@article{2fb92250cec541bd8f2e0890d4b2f15e,
title = "Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide",
abstract = "We analysed retrospective US medical claims data to evaluate longitudinal usage patterns (modification of treatment over time) for glaucoma patients receiving the ophthalmic carbonic anhydrase inhibitors (CAIs) brinzolamide or dorzolamide. Patients enrolled in a healthcare plan at least 2 months before and 6 months after their first CAI pharmacy claim were eligible. Treatment failures, patients who switched off CAI and/or added concomitant glaucoma medications, were calculated at 1, 2, and 6 months. Six hundred and twenty-six patients met the inclusion criteria, 220 for brinzolamide and 406 for dorzolamide. Overall 6 months treatment failure rates were 49.1{\%} and 53.2{\%} for brinzolamide and dorzolamide, respectively. Six month failure rate due to discontinuing CAI only were 20.9{\%} for brinzolamide and 24.6{\%} for dorzolamide, while median days to treatment failure were 160 and 106, respectively (p=0.027). Evaluation of differences in longitudinal usage patterns for CAIs may be helpful in determining appropriate treatments for glaucoma patients.",
keywords = "Carbonic anhydrase inhibitors, Glaucoma, Resource utilisation, Retrospective analysis, Treatment failure",
author = "Michael Halpern and S. Sorensen and D. Covert and J. Hutton",
year = "2000",
language = "English (US)",
volume = "3",
pages = "111--120",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",
number = "111-120",

}

TY - JOUR

T1 - Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide

AU - Halpern, Michael

AU - Sorensen, S.

AU - Covert, D.

AU - Hutton, J.

PY - 2000

Y1 - 2000

N2 - We analysed retrospective US medical claims data to evaluate longitudinal usage patterns (modification of treatment over time) for glaucoma patients receiving the ophthalmic carbonic anhydrase inhibitors (CAIs) brinzolamide or dorzolamide. Patients enrolled in a healthcare plan at least 2 months before and 6 months after their first CAI pharmacy claim were eligible. Treatment failures, patients who switched off CAI and/or added concomitant glaucoma medications, were calculated at 1, 2, and 6 months. Six hundred and twenty-six patients met the inclusion criteria, 220 for brinzolamide and 406 for dorzolamide. Overall 6 months treatment failure rates were 49.1% and 53.2% for brinzolamide and dorzolamide, respectively. Six month failure rate due to discontinuing CAI only were 20.9% for brinzolamide and 24.6% for dorzolamide, while median days to treatment failure were 160 and 106, respectively (p=0.027). Evaluation of differences in longitudinal usage patterns for CAIs may be helpful in determining appropriate treatments for glaucoma patients.

AB - We analysed retrospective US medical claims data to evaluate longitudinal usage patterns (modification of treatment over time) for glaucoma patients receiving the ophthalmic carbonic anhydrase inhibitors (CAIs) brinzolamide or dorzolamide. Patients enrolled in a healthcare plan at least 2 months before and 6 months after their first CAI pharmacy claim were eligible. Treatment failures, patients who switched off CAI and/or added concomitant glaucoma medications, were calculated at 1, 2, and 6 months. Six hundred and twenty-six patients met the inclusion criteria, 220 for brinzolamide and 406 for dorzolamide. Overall 6 months treatment failure rates were 49.1% and 53.2% for brinzolamide and dorzolamide, respectively. Six month failure rate due to discontinuing CAI only were 20.9% for brinzolamide and 24.6% for dorzolamide, while median days to treatment failure were 160 and 106, respectively (p=0.027). Evaluation of differences in longitudinal usage patterns for CAIs may be helpful in determining appropriate treatments for glaucoma patients.

KW - Carbonic anhydrase inhibitors

KW - Glaucoma

KW - Resource utilisation

KW - Retrospective analysis

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=0034489109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034489109&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034489109

VL - 3

SP - 111

EP - 120

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 111-120

ER -